Drug lookup
Drug reference

Escitalopram + Clonazepam

SSRI · Antidepressant, Anxiolytic

Also known as Nexito Plus, Eslopam Plus, S-Cetapram Plus, Elpram Plus, D'citalopam Plus

SSRIAntidepressant, AnxiolyticATC N06AB10 (Escitalopram), N03AE01 (Clonazepam)
CDSCO approvedSchedule HATC N06AB10 (Escitalopram), N03AE01 (Clonazepam)
Pharmacokineticsplasma · t hours
1.5wONSET2.5hPEAK1.2d9hDURATION
ONSET
1.5w · Escitalopram: Initial anxiolytic effects may be seen within 1-2 weeks; full antidepressant effect within 2-4 weeks. Clonazepam: 20-60 minutes.
PEAK
2.5h · Escitalopram: Approximately 5 hours. Clonazepam: 1-4 hours.
1.2d · Escitalopram: Approximately 27-32 hours. Clonazepam: 18-50 hours.
DURATION
9h · Escitalopram: Extended (due to long half-life). Clonazepam: 6-12 hours (anticonvulsant); anxiolytic effects can last longer.
EXCRETION
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
D (due to Clonazepam)
FDA category + note
Top interactionssee all 12
  • Aceclofenac + ParacetamolSevereTextbookKDT 7e
  • AceclofenacSevereTextbookKDT 7e
  • AspirinSevereTextbookKDT 7e
  • BromfenacSevereTextbookKDT 7e

Mechanism

Escitalopram selectively inhibits serotonin reuptake, increasing serotonin levels in the synaptic cleft, leading to antidepressant and anxiolytic effects over time. Clonazepam, a benzodiazepine, enhances the effect of gamma-aminobutyric acid (GABA) at GABAA receptors, resulting in rapid anxiolytic, sedative, muscle relaxant, and anticonvulsant properties. The combination provides immediate symptomatic relief of anxiety and panic through clonazepam while escitalopram works to address the underlying mood disorder. Combination rationale: This fixed-dose combination aims to provide rapid symptomatic relief of anxiety or panic through the immediate action of clonazepam, while escitalopram initiates its slower-acting but sustained antidepressant and anxiolytic effects. This approach helps manage acute symptoms during the initial latency period of SSRI action, potentially improving patient adherence and outcomes, particularly in conditions where severe anxiety or panic is prominent.

Indications

Generalized anxiety disorder (GAD)Panic disorder with or without agoraphobiaMajor depressive disorder with significant anxiety symptomsSocial anxiety disorder

Dosing

Adult
Oral, usually once daily. Common starting strengths include Escitalopram 5 mg + Clonazepam 0.25 mg or Escitalopram 10 mg + Clonazepam 0.5 mg. Dosage may be titrated based on response and tolerability, typically Escitalopram 10-20 mg/day and Clonazepam 0.25-1 mg/day. Clonazepam should be tapered gradually when discontinuing.
Pediatric
Not recommended for children and adolescents under 18 years due to lack of established safety and efficacy.
Renal adjustment
Escitalopram: Mild to moderate impairment, no dose adjustment; severe impairment, caution. Clonazepam: Use with caution, consider lower doses or extended intervals in severe renal impairment.
Hepatic adjustment
Escitalopram: Caution, consider lower starting dose (e.g., 5 mg/day) and slower titration in mild to moderate impairment; contraindicated in severe impairment. Clonazepam: Contraindicated in severe hepatic impairment; use with caution in mild to moderate impairment, lower doses may be necessary.
Geriatric
Lower initial doses recommended (e.g., Escitalopram 5 mg/day + Clonazepam 0.25 mg/day) due to increased sensitivity and slower clearance; titrate carefully. Increased risk of falls and cognitive impairment.
Max dose
Typically Escitalopram 20 mg/day + Clonazepam 1 mg/day, though higher doses of clonazepam might be used in severe cases under strict medical supervision for short periods.

Pharmacokinetics

Onset
Escitalopram: Initial anxiolytic effects may be seen within 1-2 weeks; full antidepressant effect within 2-4 weeks. Clonazepam: 20-60 minutes.
Peak effect
Escitalopram: Approximately 5 hours. Clonazepam: 1-4 hours.
Duration
Escitalopram: Extended (due to long half-life). Clonazepam: 6-12 hours (anticonvulsant); anxiolytic effects can last longer.
Half-life
Escitalopram: Approximately 27-32 hours. Clonazepam: 18-50 hours.
Bioavailability
Escitalopram: Approximately 80%. Clonazepam: Approximately 90%.
Protein binding
Escitalopram: Approximately 56%. Clonazepam: Approximately 85%.
Metabolism
Escitalopram: Hepatic, primarily via CYP2C19, CYP3A4, and CYP2D6 to inactive metabolites. Clonazepam: Hepatic, primarily via nitroreduction by CYP3A4, followed by N-acetylation to inactive metabolites.
Excretion
Escitalopram: Primarily renal (approximately 27% as unchanged drug) and hepatic. Clonazepam: Primarily renal as metabolites (less than 2% as unchanged drug).

Contraindications

  • Hypersensitivity to escitalopram, clonazepam, or any excipients
  • Concomitant use with Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing an MAOI
  • Acute narrow-angle glaucoma
  • Severe respiratory insufficiency
  • Severe hepatic impairment
  • Pregnancy (especially first trimester for clonazepam)

Side effects

Common
DrowsinessDizzinessNauseaFatigueHeadacheInsomniaDry mouthConstipationDiarrheaSexual dysfunction (especially escitalopram)Weight gain/lossBlurred vision
Serious
  • Serotonin syndrome (agitation, hallucinations, tachycardia, hyperthermia, incoordination)
  • Suicidal ideation (especially in young adults)
  • Respiratory depression (clonazepam)
  • Physical and psychological dependence (clonazepam)
  • Withdrawal symptoms upon abrupt discontinuation
  • Severe allergic reactions
  • Seizures (upon clonazepam withdrawal)
  • Extrapyramidal symptoms
  • Hyponatremia (escitalopram)

Pregnancy & lactation

Pregnancy

D (due to Clonazepam)

Lactation

Both escitalopram and clonazepam are excreted into breast milk. Not recommended during breastfeeding due to potential for sedation, feeding difficulties, and withdrawal symptoms in the infant. A risk-benefit assessment should be performed if absolutely necessary, with careful monitoring of the infant.

Drug interactions

Aceclofenac + Paracetamol
Severe
Textbook

Increased risk of gastrointestinal bleed.

Monitor for bleeding; consider gastroprotective agents or alternative analgesics.

Source: KDT 7e

Aceclofenac
Severe
Textbook

Increased risk of gastrointestinal bleed.

Monitor for bleeding; consider gastroprotective agents or alternative analgesics.

Source: KDT 7e

Aspirin
Severe
Textbook

Increased risk of gastrointestinal bleed.

Monitor for bleeding; consider gastroprotective agents or alternative analgesics.

Source: KDT 7e

Bromfenac
Severe
Textbook

Increased risk of gastrointestinal bleed.

Monitor for bleeding; consider gastroprotective agents or alternative analgesics.

Source: KDT 7e

Capsaicin
Severe
Textbook

Increased risk of gastrointestinal bleed.

Monitor for bleeding; consider gastroprotective agents or alternative analgesics.

Source: KDT 7e

Choline Salicylate
Severe
Textbook

Increased risk of gastrointestinal bleed.

Monitor for bleeding; consider gastroprotective agents or alternative analgesics.

Source: KDT 7e

Clopidogrel
Severe
Textbook

Increased bleeding risk.

Exercise extra caution and monitor for signs of bleeding.

Source: G&G 14e

Diclofenac + Paracetamol
Severe
Textbook

Increased risk of gastrointestinal bleed.

Monitor for bleeding; consider gastroprotective agents or alternative analgesics.

Source: KDT 7e

Diclofenac
Severe
Textbook

Increased risk of gastrointestinal bleed.

Monitor for bleeding; consider gastroprotective agents or alternative analgesics.

Source: KDT 7e

Etodolac
Severe
Textbook

Increased risk of gastrointestinal bleed.

Monitor for bleeding; consider gastroprotective agents or alternative analgesics.

Source: KDT 7e

Etoricoxib
Severe
Textbook

Increased risk of gastrointestinal bleed.

Monitor for bleeding; consider gastroprotective agents or alternative analgesics.

Source: KDT 7e

Flurbiprofen
Severe
Textbook

Increased risk of gastrointestinal bleed.

Monitor for bleeding; consider gastroprotective agents or alternative analgesics.

Source: KDT 7e

Related guidelines

Other SSRI drugs

Ask House about Escitalopram + Clonazepam

Continue into a citation-backed clinical answer with the drug context already attached.